AlphAIAlphAI — Financial news for AI agents
investing.comNOV 22 min read$JAZZ

Jazz Pharmaceuticals earnings missed by $10.18, revenue topped estimates

Jazz Pharmaceuticals (JAZZ) reported Q3 EPS of $-3.88, missing estimates by $10.18, but revenue of $1.24B exceeded expectations. The stock is down 16.45% over 3 months but up 54.96% year-over-year. InvestingPro rates its financial health as 'great performance'.

Original reporting
investing.com
Published Nov 2, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$JAZZ
Bullish
high confidence
Mentioned
$JAZZ
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$JAZZBullishHigh
01

Why it matters

The earnings miss is likely to trigger short‑term downside, but revenue beat may support longer‑term confidence.

02

Market read

Fresh earnings data with a significant EPS miss creates immediate trading opportunity.

03

What to watch

Revenue beat suggests underlying demand; focus on cash flow and upcoming product launches.

Relevance 7/10Novelty 8/10Timing: after-hours reaction

Background

Jazz Pharmaceuticals is a mid‑cap biotech firm; the earnings release was the first report of the Q3 results.

Company-level read

Ticker impact

$JAZZBullishHigh confidence
Context

Jazz Pharmaceuticals reported Q3 EPS of $-3.88, missing estimates by $10.18 and revenue of $1.24B versus $1.2B consensus.

Expected impact

downward pressure as market prices in the earnings shortfall

Evidence & confidence

The sizable EPS miss and negative surprise are fresh data that typically trigger a decline in the stock.

Market effects

Sector

Potential drag on biotech sector as earnings miss may raise concerns about pipeline progress.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond sector peers.

Counterpoint

What could challenge this read

If the miss is driven by one-time items, the stock could rebound on future pipeline optimism.

Key entities

  • company
    Jazz Pharmaceuticals

    Biopharmaceutical company reporting Q3 results.

Read at source← All news

StoryJazz Pharmaceuticals raises 2026 revenue outlook after Q3 earnings

Also covered by

5 outlets

Related articles

NOV 3
$JAZZMedAI 8/10

Jazz: Q3 Earnings Snapshot

Jazz Pharmaceuticals (JAZZ) reported a Q3 loss of $483.4M, or $7.48 per share, but beat estimates of $4.09 per share. Revenue was $1.24B, exceeding forecasts of $1.21B. The company expects full-year revenue between $4.78B and $4.85B.

finance.yahoo.com2 min
NOV 3
$JAZZMed

Jazz (JAZZ) Q3 2026 Earnings Call Transcript

Jazz Pharmaceuticals reported Q3 2026 earnings, highlighting 35% year-over-year growth in oncology revenues. The company increased its 2026 revenue guidance and acquired Actio Biosciences, adding ABS-1230 to its pipeline. Key products like Ziihera, Xywav, and Epidiolex drove growth, with Ziihera reaching $21 million in sales. The company also announced leadership changes, with Samantha Pearce set to retire.

finance.yahoo.com3 min
NOV 3
$JAZZMedAI 8/10

Jazz Pharmaceuticals Q3 Earnings Call Highlights

Jazz Pharmaceuticals reported Q3 net sales of $21M for Ziihera, targeting 3,000-4,000 U.S. patients annually. Oncology revenue grew 35% YoY, with Zepzelca sales up 32%. Jazz acquired Actio Biosciences for $820M, adding ABS-1230 to its pipeline. Epidiolex sales were $295M. The company maintained peak sales estimates for Ziihera and Modeyso.

finance.yahoo.com3 min